[CAS NO. 928134-65-0]  Osilodrostat (LCI699)

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [928134-65-0]

Store
Catalog
SLK-S7456
Brand
Selleck
CAS
928134-65-0

DESCRIPTION [928134-65-0]

Overview

MDLMFCD25976825
Molecular Weight227.24
Molecular FormulaC13H10FN3
SMILESFC1=C([C@@]2(N3C(CC2)=CN=C3)[H])C=CC(C#N)=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM4.4006 mL22.0032 mL44.0063 mL
5 mM0.8801 mL4.4006 mL8.8013 mL
10 mM0.4401 mL2.2003 mL4.4006 mL
50 mM0.0880 mL0.4401 mL0.8801 mL

Description

LCI699(Osilodrostat) is a potent inhibitor of , an enzyme catalyzing the final step of cortisol synthesis.

Targets

11β-hydroxylase [1]
2.5 nM

In vitro

LCI699 also inhibits aldosterone synthase (CYP11B2) other than CYP11B1.

In vivo

LCI699 is a potent inhibitor of 11β-hydroxylase (CYP11B1), the enzyme that catalyzes the final step of cortisol synthesis, and has a half-life of ∼4 hours. It decreases blood pressure (BP) in patients with essential hypertension and primary aldosteronism. Treatment with LCI699 is well tolerated, it is demonstrated efficacy with a satisfactory safety and tolerability profile in the proof-of-concept study in Cushing's disease. The administration of LCI699, up to 1.0 mg BID, effectively and safely inhibits aldosterone synthase in patients with primary aldosteronism.


Synonyms

Benzonitrile, 4-[(5R)-6,7-dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluoro-
4-[(5R)-6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl]-3-fluorobenzonitrile
LCI 699
Osilodrostat
4-(R)-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-5-yl)-3-fluorobenzonitrile
LCI 699NX
Isturisa